Single and double autotransplants for relapsing/refractory Hodgkin’s disease: results of two consecutive trials
| Autor: | J L Ascensao, Abraham Mittelman, Tauseef Ahmed, L. Helson, P. Cook, Robert A. Preti, R Kancherla, Morton Coleman, M Beer, Karen Seiter, T Akhtar, Eric J. Feldman, R Goldberg, D. E. Lake |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Transplantation Conditioning Adolescent medicine.medical_treatment Disease Vinblastine Transplantation Autologous Drug Administration Schedule Carboplatin Refractory Recurrence Antineoplastic Combined Chemotherapy Protocols medicine Humans Life Tables In patient Bone Marrow Transplantation Salvage Therapy Transplantation Chemotherapy business.industry Remission Induction Cytarabine Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Combined Modality Therapy Hodgkin Disease Survival Analysis Lymphoma Surgery Treatment Outcome medicine.anatomical_structure Retreatment Toxicity Refractory Hodgkin's Disease Female Bone marrow Mitoxantrone business Thiotepa |
| Zdroj: | Bone Marrow Transplantation. 19:449-454 |
| ISSN: | 1476-5365 0268-3369 |
| Popis: | To evaluate a strategy of one cycle of dose-intensive chemotherapy for patients with Hodgkin's disease in sensitive relapse and two cycles for those with refractory disease, 122 patients received dose-intensive chemotherapy followed by autotransplant in two consecutive studies. Patients with refractory disease were offered a second transplant with different conditioning in the absence of progression or excessive toxicity. CR was present after treatment in 46% while 16% died in the peritransplant period. Of 41 patients with primary refractory disease and 42 with refractory relapse, 24 and 21 respectively received a second cycle. Of these 45 refractory patients, 12 were in CR and 11 in PR after the first cycle and 10 of these 11 in PR achieved a durable CR with the second transplant. The CR rate is 37% in patients with refractory relapse and 19% in those with primary refractory disease. At a median follow-up of 4 years, median survival is 45 months. Progression-free survival of the refractory patients who could receive a second cycle was similar to that of patients with sensitive disease. A sequential transplant strategy is feasible. A subgroup of patients with refractory disease can achieve long-term survival after sequential BMT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|